<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003202</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066052</org_study_id>
    <secondary_id>CCCWFU-62197</secondary_id>
    <secondary_id>NCI-G98-1386</secondary_id>
    <nct_id>NCT00003202</nct_id>
  </id_info>
  <brief_title>Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer</brief_title>
  <official_title>Alternating Phase I/II Trials of Twice-Weekly Infusion Gemcitabine (2'2'-Difluoro-2'-Deoxycytidine) and Concurrent Thoracic Radiation Alone - Or Following 2 Cycles of Cisplatin/Gemcitabine Induction Chemotherapy for the Treatment of Stage IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Combining radiation therapy with chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to compare the effectiveness of gemcitabine with radiation therapy&#xD;
      alone or following two-drug combination chemotherapy in treating patients with stage III&#xD;
      non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of twice-weekly gemcitabine when delivered&#xD;
           concurrently with thoracic radiotherapy alone or following 2 cycles of induction&#xD;
           chemotherapy in patients with Stage IIIA or IIIB non-small cell lung cancer.&#xD;
&#xD;
        -  Assess the toxicity of concurrent thoracic radiation and gemcitabine in these patients.&#xD;
&#xD;
        -  Determine the effectiveness of concurrent radiation and gemcitabine by determining the&#xD;
           complete response rate, partial response rate, time to recurrence, pattern of&#xD;
           recurrence, and overall survival in a cohort of these patients.&#xD;
&#xD;
      OUTLINE: This is an alternating two arm, dose escalation, multicenter study.&#xD;
&#xD;
      Arm I: Patients receive twice-weekly gemcitabine as a 30 minute infusion. Concurrent&#xD;
      radiation therapy is administered 5 days a week for 6 weeks.&#xD;
&#xD;
      Arm II: Patients receive 2 cycles of induction chemotherapy consisting of gemcitabine as a 30&#xD;
      minute infusion on day 1 and 8 and cisplatin IV over 1 hour on day 1. Each cycle is 21 days.&#xD;
      Patients then receive gemcitabine and radiation therapy as in arm I.&#xD;
&#xD;
      Cohorts of 3 patients are enrolled into each treatment arm at each dose level of gemcitabine.&#xD;
      Toxicity for each arm is assessed independently. Once dose limiting toxicity (DLT) is&#xD;
      observed at any dose level, 3 more patients are enrolled at the same dose level. The maximum&#xD;
      tolerated dose (MTD) is defined as the dose at which no more than 1 of 6 patients experiences&#xD;
      grade 4 toxicity, or no more than 4 of 6 patients experience grade 3 or worse toxicity (DLT).&#xD;
      After the MTD is determined for each treatment arm, additional patients are treated at that&#xD;
      dose level for the phase II portion of the study.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, then every 4 months for the next 2 years,&#xD;
      and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: There will be approximately 24-48 patients accrued into this study within&#xD;
      1-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1998</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">April 2002</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>â€¢Determine the maximum tolerated dose of twice-weekly gemcitabine when delivered concurrently with thoracic radiotherapy</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>assess the efficacy of dose of twice-weekly gemcitabine when delivered concurrently with thoracic radiotherapy</measure>
    <time_frame>72 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage IIIA or IIIB non-small cell lung cancer that is&#xD;
             unicentric and inoperable, including the following cellular types:&#xD;
&#xD;
               -  Squamous cell carcinoma&#xD;
&#xD;
               -  Adenocarcinoma&#xD;
&#xD;
               -  Bronchoalveolar carcinoma&#xD;
&#xD;
               -  Large cell anaplastic carcinoma&#xD;
&#xD;
               -  Non-small cell lung cancer not otherwise specified&#xD;
&#xD;
          -  Tumors may be multifocal if all of disease is believed to be result of direct spread&#xD;
&#xD;
          -  Disease must be fully accessible by radiotherapy ports for the entire prescribed dose&#xD;
&#xD;
          -  No supraclavicular nodes or diffuse pleural involvement&#xD;
&#xD;
          -  No contralateral hilar disease or an exudative, bloody, or cytologically malignant&#xD;
             effusion&#xD;
&#xD;
          -  Measurable disease required for phase II of this study&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 1 year&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin greater than 10 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  BUN no greater than 1.5 times normal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times normal&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV1 no greater than 1 liter except if tumor has negatively impacted&#xD;
&#xD;
          -  pulmonary function&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other serious medical or psychiatric illness&#xD;
&#xD;
          -  No prior lung cancer except if free of disease for more than 3 years&#xD;
&#xD;
          -  No other prior malignancy except nonmelanoma skin cancer or if free of&#xD;
&#xD;
          -  disease for more than 1 year&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior thoracic radiotherapy&#xD;
&#xD;
          -  Concurrent radiotherapy to other anatomic sites allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur William Blackstock, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>November 25, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2003</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>adenosquamous cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

